QED Therapeutics Revenue and Competitors

Claim your profile

Location

$65M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • QED Therapeutics's estimated annual revenue is currently $5.7M per year.(i)
  • QED Therapeutics received $65.0M in venture funding in January 2018.
  • QED Therapeutics's estimated revenue per employee is $77,500
  • QED Therapeutics's total funding is $65M.

Employee Data

  • QED Therapeutics has 74 Employees.(i)
  • QED Therapeutics grew their employee count by -11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

keywords:N/A

$65M

Total Funding

74

Number of Employees

$5.7M

Revenue (est)

-11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

QED Therapeutics News

2022-04-17 - HER2 negative Breast Cancer Pipeline Insights | Research Report 2022 by DelveInsight

... HER2 negative Breast Cancer treatment therapies, as per DelveInsight ... QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer,...

2019-09-05 - BridgeBio Launches New Subsidiary to Tackle Limb-Girdle ...

Sarepta Therapeutics is also focused on the disease. ... comes about a year after BridgeBio launched QED Therapeutics to develop infigratinib, ...

2019-06-03 - QED Therapeutics Presents New Data on the Potential for ...

SAN FRANCISCO, June 3, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of data demonstrating the clinical ...

2019-04-01 - Preclinical Data Demonstrates the Potential of QED ...

SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of preclinical data demonstrating the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.7M74N/AN/A
#2
$13M7454%N/A
#3
$9.1M75-23%$20M
#4
N/A75400%N/A
#5
$9.8M754%N/A

QED Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-01-31$65.0MUndisclosedBridgeBio PharmaArticle